The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer

Anticancer effect of nor-wogonin (5, 7, 8-trihydroxyflavone) on human triple-negative breast cancer cells via downregulation of TAK1, NF-κB, and STAT3

(2019) Amer Ali Abd El-Hafeez et al.   Pharmacological Reports

Fomes fomentarius Ethanol Extract Exerts Inhibition of Cell Growth and Motility Induction of Apoptosis via Targeting AKT in Human Breast Cancer MDA-MB-231 Cells

(2019) Seon-OK Lee et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer

(2019) Nicole M. Kettner et al.   CLINICAL CANCER RESEARCH

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer

(2019) Gaia Giannone et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer

(2019) Sobhani et al.   Cells

MiR-128-3p suppresses breast cancer cellular progression via targeting LIMK1

(2019) Junyong Zhao et al.   BIOMEDICINE & PHARMACOTHERAPY

Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients

(2019) Marzia Del Re et al.   BREAST CANCER RESEARCH AND TREATMENT

Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19

(2019) Pengfei Zheng et al.   HISTOCHEMISTRY AND CELL BIOLOGY

Resveratrol chemosensitizes adriamycin‐resistant breast cancer cells by modulating miR‐122‐5p

(2019) Wei Zhang et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Upregulation of hsa_circ_0136666 contributes to breast cancer progression by sponging miR‐1299 and targeting CDK6

(2019) Li‐Hong Liu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

The microRNA‐141‐3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab

(2019) Wenqing Song et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

LINC00511 knockdown enhances paclitaxel cytotoxicity in breast cancer via regulating miR-29c/CDK6 axis

(2019) Hualong Zhang et al.   LIFE SCIENCES

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

(2019) Seock-Ah Im et al.   NEW ENGLAND JOURNAL OF MEDICINE

Icariin induces apoptosis by suppressing autophagy in tamoxifen-resistant breast cancer cell line MCF-7/TAM

(2019) Xia Cheng et al.   Breast Cancer

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)

(2019) Concepción Sánchez-Martínez et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer

(2019) Victor Quereda et al.   CANCER CELL

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

(2019) Sara A. Hurvitz et al.   CLINICAL CANCER RESEARCH

A clinical evaluation of treatments that target cell cycle machinery in breast cancer

(2019) Palma Fedele et al.   EXPERT OPINION ON PHARMACOTHERAPY

Antitumor Activity of Vanicoside B Isolated from Persicaria dissitiflora by Targeting CDK8 in Triple-Negative Breast Cancer Cells

(2019) Donghwa Kim et al.   JOURNAL OF NATURAL PRODUCTS

CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer

(2019) Lei Nie et al.   Nature Communications

An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer

(2019) Vera E. van der Noord et al.   Scientific Reports

Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo

(2019) Ramesh Elango et al.   Scientific Reports

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells

(2019) Daniele Cretella et al.   Scientific Reports

MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance, and Applications in Human Triple-Negative Breast Cancer

(2019) Lei Ding et al.   Cells

PA28α/β Promote Breast Cancer Cell Invasion and Metastasis via Down-Regulation of CDK15

(2019) Shengnan Li et al.   Frontiers in Oncology

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

(2019) Dennis J. Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Panduratin A Inhibits Cell Proliferation by Inducing G0/G1 Phase Cell Cycle Arrest and Induces Apoptosis in Breast Cancer Cells

(2018) Qiuming Liu et al.   Biomolecules & Therapeutics

Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer

(2018) Yoshimi Imawari et al.   CANCER SCIENCE

Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer

(2018) Laura Spring et al.   CLINICAL CANCER RESEARCH

The Emerging Picture of CDK11: Genetic, Functional and Medicinal Aspects

(2018) Nikolas Ferreira dos Santos Paparidis et al.   CURRENT MEDICINAL CHEMISTRY

C-glycosyl flavone from Urginea indica inhibits proliferation & angiogenesis & induces apoptosis via cyclin-dependent kinase 6 in human breast, hepatic & colon cancer cell lines

(2018) RamaRao Malla et al.   INDIAN JOURNAL OF MEDICAL RESEARCH

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

(2018) Dennis J. Slamon et al.   JOURNAL OF CLINICAL ONCOLOGY

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

(2018) Debu Tripathy et al.   LANCET ONCOLOGY

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

(2018) Chrysiis Michaloglou et al.   MOLECULAR CANCER THERAPEUTICS

Loss of Cdk5 in breast cancer cells promotes ROS-mediated cell death through dysregulation of the mitochondrial permeability transition pore

(2018) Saranya NavaneethaKrishnan et al.   ONCOGENE

Galangin Induces Apoptosis in MCF-7 Human Breast Cancer Cells Through Mitochondrial Pathway and Phosphatidylinositol 3-Kinase/Akt Inhibition

(2018) Dan Liu et al.   PHARMACOLOGY

The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response

(2018) Giancarlo Barone et al.   Oncotarget

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

(2018) Juan Jin et al.   NEOPLASIA

Targeting the cell cycle in breast cancer: towards the next phase

(2018) KL Thu et al.   CELL CYCLE

The Dual Role of MicroRNAs in Colorectal Cancer Progression

(2018) Lei Ding et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

(2018) Tarah J. Ballinger et al.   Frontiers in Oncology

Activated kinase screening identifies the IKBKE oncogene as a positive regulator of autophagy

(2018) Margherita Leonardi et al.   Autophagy

Rhomboid domain-containing protein 1 promotes breast cancer progression by regulating the p-Akt and CDK2 levels

(2018) Xin Zhang et al.   Cell Communication and Signaling

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

(2018) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Keeping CDK18 in balance to prevent DNA replication stress in breast cancer

(2018) Esmée Braams et al.   Oncotarget

miR-455 inhibits breast cancer cell proliferation through targeting CDK14

(2017) Bing Wang et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study

(2017) Ling-Chu Chang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

(2017) George W. Sledge et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast Cancer

(2017) Kalnisha Naidoo et al.   MOLECULAR CANCER THERAPEUTICS

CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion

(2017) Jerry F. Tien et al.   NUCLEIC ACIDS RESEARCH

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin‐Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations

(2017) Laura M. Spring et al.   ONCOLOGIST

Inhibitors of cyclin-dependent kinases as cancer therapeutics

(2017) Steven R. Whittaker et al.   PHARMACOLOGY & THERAPEUTICS

CDK8: a new breast cancer target

(2017) John Crown   Oncotarget

The awakening of the CDK10/Cyclin M protein kinase

(2017) Vincent J. Guen et al.   Oncotarget

Mechanisms of the anti-tumor activity of Methyl 2-(-5-fluoro-2-hydroxyphenyl)-1 H-benzo[d]imidazole-5-carboxylate against breast cancer in vitro and in vivo

(2017) Mohadeseh Hasanpourghadi et al.   Oncotarget

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study

(2016) G. Curigliano et al.   BREAST

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer

(2016) Romualdo Barroso-Sousa et al.   Breast Care

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

(2016) J. R. Infante et al.   CLINICAL CANCER RESEARCH

Cyclin-Dependent Kinase 14 Promotes Cell Proliferation, Migration and Invasion in Ovarian Cancer by Inhibiting Wnt Signaling Pathway

(2016) Jun Ou-Yang et al.   GYNECOLOGIC AND OBSTETRIC INVESTIGATION

The RNA Polymerase II CTD: The Increasing Complexity of a Low-Complexity Protein Domain

(2016) Célia Jeronimo et al.   JOURNAL OF MOLECULAR BIOLOGY

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

(2016) Massimo Cristofanilli et al.   LANCET ONCOLOGY

Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer

(2016) N. A. Jabbour-Leung et al.   MOLECULAR CANCER THERAPEUTICS

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

(2016) P. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

(2016) Giampaolo Bianchini et al.   Nature Reviews Clinical Oncology

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

(2016) Gabriel N. Hortobagyi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human CDK18 promotes replication stress signaling and genome stability

(2016) Giancarlo Barone et al.   NUCLEIC ACIDS RESEARCH

Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future

(2016) Adam J. DiPippo et al.   PHARMACOTHERAPY

Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity

(2016) R. D. Dorand et al.   SCIENCE

Insights into APC/C: from cellular function to diseases and therapeutics

(2016) Zhuan Zhou et al.   Cell Division

Potential role of PCTAIRE-2, PCTAIRE-3 and P-Histone H4 in amyloid precursor protein-dependent Alzheimer pathology

(2016) Dale Chaput et al.   Oncotarget

The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer

(2016) Yubing Zhou et al.   Oncotarget

CDK4/6 inhibitors in breast cancer

(2015) Tim Dukelow et al.   ANTI-CANCER DRUGS

Critical role of CDK11p58 in human breast cancer growth and angiogenesis

(2015) Yayun Chi et al.   BMC CANCER

CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer

(2015) Yubao Wang et al.   CELL

PCTAIRE1/PCTK1/CDK16: a new oncotarget?

(2015) Teruki Yanagi et al.   CELL CYCLE

FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer

(2015) J. A. Beaver et al.   CLINICAL CANCER RESEARCH

The Molecular Biology of Spindle Assembly Checkpoint Signaling Dynamics

(2015) Andrea Musacchio   CURRENT BIOLOGY

Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer

(2015) Eugenia Broude et al.   CURRENT CANCER DRUG TARGETS

miRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer

(2015) Andrea Mathe et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia

(2015) Mark C. Lanasa et al.   LEUKEMIA RESEARCH

Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing

(2015) Kaiwei Liang et al.   MOLECULAR AND CELLULAR BIOLOGY

The history and future of targeting cyclin-dependent kinases in cancer therapy

(2015) Uzma Asghar et al.   NATURE REVIEWS DRUG DISCOVERY

Spatiotemporal regulation of the anaphase-promoting complex in mitosis

(2015) Sushama Sivakumar et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The Mediator complex: a central integrator of transcription

(2015) Benjamin L. Allen et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers

(2015) Loredana Santo et al.   SEMINARS IN ONCOLOGY

Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report

(2015) Yanjie You et al.   CELLULAR ONCOLOGY

Cyclin-dependent kinase 11p110 (CDK11p110) is crucial for human breast cancer cell proliferation and growth

(2015) Yubing Zhou et al.   Scientific Reports

PCTAIRE1-Knockdown Sensitizes Cancer Cells to TNF Family Cytokines

(2015) Teruki Yanagi et al.   PLoS One

Phylogenetic analysis of CDK and cyclin proteins in premetazoan lineages

(2014) Lihuan Cao et al.   BMC EVOLUTIONARY BIOLOGY

The Mediator complex: a master coordinator of transcription and cell lineage development

(2014) J.-w. Yin et al.   DEVELOPMENT

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

(2014) Lawrence M. Gelbert et al.   INVESTIGATIONAL NEW DRUGS

Integrated Analysis of Whole Genome and Transcriptome Sequencing Reveals Diverse Transcriptomic Aberrations Driven by Somatic Genomic Changes in Liver Cancers

(2014) Yuichi Shiraishi et al.   PLoS One

Cyclin-dependent kinases

(2014) Marcos Malumbres   GENOME BIOLOGY

The two faces of Cdk8, a positive/negative regulator of transcription

(2013) Josipa Nemet et al.   BIOCHIMIE

The Role of Cdk5 in Neuroendocrine Thyroid Cancer

(2013) Karine Pozo et al.   CANCER CELL

HIF1A Employs CDK8-Mediator to Stimulate RNAPII Elongation in Response to Hypoxia

(2013) Matthew D. Galbraith et al.   CELL

The Writers, Readers, and Functions of the RNA Polymerase II C-Terminal Domain Code

(2013) Célia Jeronimo et al.   CHEMICAL REVIEWS

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

(2013) Monica M. Mita et al.   Clinical Breast Cancer

Cdks, cyclins and CKIs: roles beyond cell cycle regulation

(2013) S. Lim et al.   DEVELOPMENT

The C-Terminal Domain of Rpb1 Functions on Other RNA Polymerase II Subunits

(2013) Hyunsuk Suh et al.   MOLECULAR CELL

RB1 Status in Triple Negative Breast Cancer Cells Dictates Response to Radiation Treatment and Selective Therapeutic Drugs

(2013) Tyler J. W. Robinson et al.   PLoS One

CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression

(2013) Qian Liang et al.   Scientific Reports

Cyclin dependent kinases in cancer

(2012) Miriam Canavese et al.   CANCER BIOLOGY & THERAPY

The Spindle Assembly Checkpoint

(2012) Pablo Lara-Gonzalez et al.   CURRENT BIOLOGY

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition

(2012) Dai Horiuchi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

The hard facts

(2012) Amy Maxmen   NATURE

Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II

(2012) Stéphane Larochelle et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Cyclin K goes with Cdk12 and Cdk13

(2012) Jiri Kohoutek et al.   Cell Division

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

(2011) G K Schwartz et al.   BRITISH JOURNAL OF CANCER

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

(2011) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes

(2011) D. Blazek et al.   GENES & DEVELOPMENT

The CDK inhibitors in cancer research and therapy

(2011) Jonas Cicenas et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Cdc14 phosphatase promotes segregation of telomeres through repression of RNA polymerase II transcription

(2011) Andres Clemente-Blanco et al.   NATURE CELL BIOLOGY

CYY-1/Cyclin Y and CDK-5 Differentially Regulate Synapse Elimination and Formation for Rewiring Neural Circuits

(2011) Mikyoung Park et al.   NEURON

Cdc14b regulates mammalian RNA polymerase II and represses cell cycle transcription

(2011) María Guillamot et al.   Scientific Reports

Two Cyclin-Dependent Kinase Pathways Are Essential for Polarized Trafficking of Presynaptic Components

(2010) Chan-Yen Ou et al.   CELL

CDK Inhibitors: From the Bench to Clinical Trials

(2010) Flavio Rizzolio et al.   CURRENT DRUG TARGETS

Progressive Activation of CyclinB1-Cdk1 Coordinates Entry to Mitosis

(2010) Olivier Gavet et al.   DEVELOPMENTAL CELL

Cell Cycle-dependent Regulation of the Forkhead Transcription Factor FOXK2 by CDK·Cyclin Complexes

(2010) Anett Marais et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

Emerging links between CDK cell cycle regulators and Wnt signaling

(2010) Gary Davidson et al.   TRENDS IN CELL BIOLOGY

High cyclin B1 expression is associated with poor survival in breast cancer

(2009) K Aaltonen et al.   BRITISH JOURNAL OF CANCER

A Conserved Phosphorylation Site within the Forkhead Domain of FoxM1B Is Required for Its Activation by Cyclin-CDK1

(2009) Yi-Ju Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease

(2009) Thomas S. Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

TFIIH and P-TEFb Coordinate Transcription with Capping Enzyme Recruitment at Specific Genes in Fission Yeast

(2009) Laia Viladevall et al.   MOLECULAR CELL

Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer

(2008) Elizabeth Iorns et al.   CANCER CELL

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

Characterization of Cyclin L1 and L2 Interactions with CDK11 and Splicing Factors

(2008) Pascal Loyer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

CDK8 is a colorectal cancer oncogene that regulates β-catenin activity

(2008) Ron Firestein et al.   NATURE